Viveash Dawn 4
4 · Orexigen Therapeutics, Inc. · Filed Nov 4, 2009
Insider Transaction Report
Form 4
Viveash Dawn
Head of Regulatory Affairs
Transactions
- Award
Stock Option (right to buy)
2009-11-02+200,000→ 200,000 totalExercise: $6.73Exp: 2019-11-01→ Common Stock (200,000 underlying)
Footnotes (2)
- [F1]25% of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on 11/01/2010 and 1/48th of the shares of stock subject to the option (rounded down to the next whole number of shares) shall vest on the same day of each month thereafter, so that all of the shares of stock subject to the option shall be vested on 11/01/2013, subject to the reporting person's continued service relationship (whether as an employee, director or consultant) with the Company or any parent or subsidiary of the Company on each such date.
- [F2]Not applicable.